Safety and Efficacy of Meloxicam Compared to Other Nonsteroidal Antiinflammatory Drugs (NSAIDs) in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, Neck, Shoulder and Arm Syndrome

Safety and Efficacy of Meloxicam (MOBIC) Compared to Other NSAIDs in Approved Therapeutic Dosages and Routes of Administration in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, Neck, Shoulder and Arm Syndrome

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02180516

Enrollment

9984

Registered

2014-07-02

Start date

2001-10-31

Completion date

Unknown

Last updated

2014-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthritis, Rheumatoid

Brief summary

Study to assess the safety profile of meloxicam by comparing incidence of gastrointestinal adverse events of meloxicam with that of NSAID in the routine daily therapeutic situation.

Interventions

DRUGMeloxicam

DRUGOther Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients with Indications according to the package insert of the prescribed NSAID

Exclusion criteria

* There is no exclusion criterion, because this Post Marketing Study is an observational study

Design outcomes

Primary

Measure	Time frame
Incidence for adverse event of gastrointestinal disorder	up to 6 months

Secondary

Measure	Time frame
Incidence for adverse drug reaction of gastrointestinal disorder	up to 6 months
Incidence of adverse events	up to 6 months
Incidence of adverse drug reactions	up to 6 months
Incidence of serious adverse events	up to 6 months
Incidence for adverse events Perforation, Ulcer and Bleeding (PUB) in the upper gastrointestinal tract	up to 6 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026